ClinicalTrials.gg
CompletedNCT04738123Updated Dec 9, 2024Results posted

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules and Placebo in Schizophrenia and Schizophrenia; Psychosis, sponsored by Karuna Therapeutics. Completed at 32 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Karuna Therapeutics (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Enrollment
6th of 20
256 · median 178
Started
2021
with 3 others
Phase 3
14 of 20
4 open now
Registered
4th of 20
by date
Lead sponsor
5 of 20
Karuna Therapeutics

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 14 in phase 3, and was the 4th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and Statistical Manual Fifth Edition (DSM-5) diagnosis of schizophrenia. The primary objective of the study is to assess the efficacy of KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily [BID]) versus placebo in reducing Positive and Negative Syndrome Scale (PANSS) total scores in adult inpatients with a DSM-5 diagnosis of schizophrenia. The secondary objectives of the study are to evaluate improvement in disease severity and symptoms, safety and tolerability, and pharmacokinetics in adult inpatients with a DSM-5 diagnosis of schizophrenia.

03

Conditions studied

  • Schizophrenia
  • Schizophrenia; Psychosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is aged 18 to 65 years, inclusive, at screening.
  2. Subject is capable of providing .

    1. A signed informed consent form must be provided before any study assessments are performed.
    2. Subject must be fluent (oral and written) in English or local language to consent
  3. Subject has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the criteria and confirmed by Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorder Studies (MINI) version 7.0.2.
  4. Subject is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening.

    1. The subject requires hospitalization for this acute exacerbation or relapse of psychotic symptoms.
    2. If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening.
  5. Positive and Negative Syndrome Scale total score between 80 and 120, inclusive. Score of ≥4 (moderate or greater) for ≥2 of the following Positive Scale (P) items:

    1. Item 1 (P1; delusions)
    2. Item 2 (P2; conceptual disorganization)
    3. Item 3 (P3; hallucinatory behavior)
    4. Item 6 (P6; suspiciousness/persecution)
  6. Subjects with no change (improvement) in PANSS total score between screening and baseline (Day -1) of more than 20%.
  7. Subject has a CGI-S score of ≥4 at screening and baseline (Day -1) visits.
  8. Subject will have been off lithium therapy for at least 2 weeks before baseline and free of all oral antipsychotic medications for at least 5 half-lives or 1 week, whichever is longer, before baseline (Day -1).
  9. Subjects taking a long-acting injectable antipsychotic could not have received a dose of medication for at least 12 weeks (24 weeks for INVEGA TRINZA) before baseline visit (Day -1).
  10. Subject is willing and able to be confined to an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements.
  11. must be ≥18 and ≤40 kg/m2.
  12. Subject resides in a stable living situation and is anticipated to return to that same stable living situation after discharge, in the opinion of the investigator.
  13. Subject has an identified reliable informant/caregiver.
  14. Women of , or men with sexual partners of childbearing potential, must be able and willing to use at least 1 highly effective method of during the study and for 30 days after the last dose of study drug. Sperm donation is not allowed for 30 days after the final dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Any primary disorder other than schizophrenia within 12 months before screening (confirmed using MINI version 7.0.2 at screening). Symptoms of mild mood dysphoria or anxiety are allowed as long as these symptoms are not the primary focus of treatment. A screening subject with mild substance abuse disorder within the 12 months before screening must be discussed and agreed upon with the medical monitor before they can be allowed into the study.
  2. Subjects who are newly diagnosed or are experiencing their first treated episode of schizophrenia.
  3. History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results.
  4. Subjects with , cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections based on either medical history or liver function test results.
  5. History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma.
  6. History of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months.
  7. Risk for suicidal behavior during the study as determined by the investigator's clinical assessment and Columbia-Suicide Severity Rating Scale (C-SSRS).
  8. Clinically significant abnormal finding on the physical examination, medical history, , or clinical laboratory results at screening.
  9. Subjects cannot currently (within 5 half-lives or 1 week, whichever is longer, before baseline [Day -1]) be receiving oral antipsychotic medications; monoamine oxidase inhibitors; anticonvulsants (eg, lamotrigine, Depakote); tricyclic antidepressants (eg, imipramine, desipramine); selective serotonin reuptake inhibitors; or any other psychoactive medications except for as needed anxiolytics (eg, lorazepam, chloral hydrate).
  10. Pregnant, lactating, or less than 3 months postpartum.
  11. If, in the opinion of the investigator (and/or Sponsor), subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the investigator (and/or Sponsor), may compromise the safety of the subject or affect his/her ability to adhere to the protocol visit schedule or fulfill visit requirements.
  12. Positive test for coronavirus (COVID-19) within 2 weeks before screening and at screening.
  13. Subjects with extreme concerns relating to global pandemics, such as COVID-19, that preclude study participation.
  14. Subject has had psychiatric hospitalization(s) for more than 30 days (cumulative) during the 90 days before screening.
  15. Subject has a history of treatment resistance to schizophrenia medications defined as failure to respond to 2 adequate courses of pharmacotherapy (a minimum of 4 weeks at an adequate dose per the label) or required clozapine within the last 12 months.
  16. Subjects with prior exposure to KarXT.
  17. Subjects who experienced any adverse effects due to xanomeline or trospium.
  18. Participation in another clinical study in which the subject received an experimental or drug agent within 3 months before screening.
  19. Risk of violent or destructive behavior.
  20. Current involuntary hospitalization or incarceration.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    KarXT

    Drug: Xanomeline and Trospium Chloride Capsules

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugXanomeline and Trospium Chloride Capsules

    Drug pages: Xanomeline · Trospium chloride

    Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.

  • DrugPlacebo

    Placebo Capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5

    The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of participants with schizophrenia and is widely used in the study of antipsychotic therapy. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility, and the negative symptoms in schizophrenia are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as the PANSS score at screening.

    Time frame: From baseline up to Week 5

Secondary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5

    PANSS positive score is the sum of all PANSS 7 positive symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility. If a patient has a PANSS assessment recorded and no more than 2 items are missing from the PANSS positive scales, then the PANSS Positive Score will be calculated as the average of the non-missing items multiplied by 7. If 3 or more items are missing (\> 30%) at a particular visit, the respective positive score at the visit will not be calculated and will be treated as missing data. Baseline is defined as the PANSS score at screening.

    Time frame: From baseline up to Week 5

  2. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5

    PANSS negative score is the sum of all PANSS 7 negative symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The negative symptoms in schizophrenia are the diminution or loss of normal functions. If a participant has a PANSS assessment recorded, and no more than 2 items are missing from the PANSS negative scales, then the PANSS Negative Score will be calculated as the average of the non-missing items multiplied by 7. If 3 or more items are missing (\> 30%) at a particular visit, the respective negative score at the visit will not be calculated and will be treated as missing data. Baseline is defined as the PANSS score at screening.

    Time frame: From baseline up to Week 5

  3. Positive and Negative Syndrome Scale (PANSS) Negative Marder Factor Score Change From Baseline at Week 5

    PANSS Marder factor score is the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom scale. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Baseline is defined as the PANSS score at screening.

    Time frame: From baseline up to Week 5

  4. Clinical Global Impression-Severity (CGI-S) Score Change From Baseline at Week 5

    Clinical Global Impression-Severity (CGI-S) Score is a measurement to evaluate severity and treatment response in schizophrenia. Completed independently by a clinician, the CGI-S assesses extremely ill patients, by asking 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness. The CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients. This scale reflects the total score. Baseline is defined as CGI-S score at screening. The change from baseline in total score is reported.

    Time frame: From baseline up to Week 5

  5. Number of Participants Who Achieve >=30% Reduction in Positive and Negative Symptoms Scale (PANSS) Total Score From Baseline to Week 5

    Positive and Negative Syndrome Scale (PANSS) is a scale used for measuring symptom severity of subjects with schizophrenia and is widely used in the study of antipsychotic therapy. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Subjects are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility, and the negative symptoms in schizophrenia are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as screening. Note: Floor adjusted data were used for this analysis. Floor adjusted total score = total score - 30.

    Time frame: From baseline up to Week 5

  6. Number of Participants Experiencing Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose up to Day 42

  7. Number of Participants Experiencing Cholinergic Symptom Adverse Event

    The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.

    Time frame: From first dose up to Day 42

  8. Change From Baseline in Simpson-Angus Scale Total Score (SAS)

    The Simpson-Angus Scale (SAS) is an established instrument to measure drug-related extrapyramidal syndromes. It is a 10-item testing instrument used to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. The range of scores is from 0 to 40 with increased scores indicating increased severity. Baseline is defined as the Simpson-Angus Scale score recorded on Day -1.

    Time frame: From baseline up to week 5

  9. Change From Baseline in Barnes Akathisia Rating Scale (BARS) Total Score

    The BARS for akathisia is a rating scale used to assess the severity of drug-induced akathisia, or restlessness, involuntary movements and inability to sit still. The range of scores is 0 to 14, with higher scores indicating greater severity. Baseline is defined as the BARS score recorded on Day -1.

    Time frame: From baseline up to week 5

  10. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score

    The AIMS is a rating scale that is used to measure involuntary movements known as tardive dyskinesia, which can sometimes develop as a side effect of long-term treatment with antipsychotic medications. This measurement was a 12-item scale to assess orofacial, extremity, and truncal movements as well as the overall severity, incapacitation, and the participant's level of awareness of the movements. Items are scored from 0 (none) to 4 (severe). A higher score indicates more severe dyskinesia. Baseline is defined as the AIMS score recorded on Day -1. The total score is the sum of sub scores for items 1-7. The first 7 items are used to measure the severity of abnormal movements in the orofacial region (4 items: facial muscles, lips, jaw, tongue), upper extremities (1 item), lower extremities (1 item), and trunk (1 item). Change from baseline for the total scores are reported.

    Time frame: From baseline up to week 5

  11. Number of Participants Who Experienced Weight Change

    The number of participants who lost weight, maintained their weight, or gained weight between baseline and week 5. Baseline is defined as measurements taken at screening.

    Time frame: From baseline up to week 5

  12. Change From Baseline in Body Mass Index (BMI)

    The change in Body Mass Index (BMI) from baseline up to week 5. BMI is a person's weight in kilograms divided by the square of height in meters. Baseline is defined as measurements taken at screening.

    Time frame: From baseline up to week 5

  13. Change From Baseline in Waist Circumference

    The change in waist circumference in centimeters from baseline up to week 5. Baseline is defined as measurements taken at screening.

    Time frame: From baseline up to week 5

  14. Change From Baseline in Orthostatic Vital Signs - Blood Pressure

    The change from baseline in orthostatic diastolic and systolic blood pressure measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.

    Time frame: From baseline up to week 5

  15. Change From Baseline in Orthostatic Vital Signs - Heart Rate

    The change from baseline in orthostatic heart rate measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.

    Time frame: From baseline up to week 5

  16. Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate

    The change from baseline up to Day 35 or early termination in ECG mean heart rate. Baseline is defined as measurements taken at screening.

    Time frame: From baseline up to Day 35 or early termination

  17. Number of Participants Experiencing Clinically Significant Abnormal Physical Examination Results

    The number of participants experiencing clinically significant abnormal physical examination results. Baseline is defined as measurements taken at screening.

    Time frame: From baseline up to week 5

  18. Number of Participants Experiencing Each Suicidal Ideation Scale Category as Per Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS assesses suicidal behavior and ideation on a scale with 4 general categories: suicidal ideation, intensity of ideation, suicidal behavior, and actual attempts. C-SSRS comprehensively identifies suicidal events while limiting the over identification of suicidal behavior. The C-SSRS was administered by a trained rater at the site. This study used 2 versions of the C-SSRS. At the Screening Visit, the "Lifetime" version was completed; for all subsequent visits, the "Since Last Visit" version of the C-SSRS was administered. Risk for suicidal behavior during the study was determined by the investigator's clinical assessment and C-SSRS as confirmed by the following: * Answering "Yes" on items 4 or 5 (C-SSRS - ideation) with the most recent episode occurring within the 2 months before screening, or * Answering "Yes" to any of the 5 items (C-SSRS behavior) with an episode occurring within the 12 months before screening. Non-suicidal, self-injurious behavior is not exclusionary.

    Time frame: From screening up to Day 42

  19. Area Under the Plasma Concentration-Time Curve (AUC)

    AUC is the total area under the plasma drug concentration-time curve from time zero to 12 hours after drug administration. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.

    Time frame: At days 8 and 28

  20. Maximum Concentration (Cmax)

    Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.

    Time frame: At days 8 and 28

  21. Time to Maximum Concentration (Tmax)

    Tmax is defined as the time it takes for a drug to reach the maximum concentration (Cmax) after administration of a drug. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.

    Time frame: At days 8 and 28

  22. Mean Observed Hemoglobin Levels

    The mean observed Hemoglobin levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 138 - 172 g/L Female: 121 - 151 g/L

    Time frame: From baseline up to Days 21, 35, or early temination

  23. Mean Observed Hematocrit Levels

    The mean observed Hematocrit levels are displayed in percentages as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 40.7 - 50.3% Female: 36.1 - 44.3%

    Time frame: From baseline up to Days 21, 35, or early temination

  24. Mean Observed Erythrocyte Levels

    The mean observed erythrocyte levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 4.7 - 6.1 10\^12 cells/L Female: 4.2 - 5.4 10\^12 cells/L

    Time frame: From baseline up to Days 21, 35, or early temination

  25. Mean Observed Platelets Levels

    The mean observed platelet levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 150-450 10\^9 cells/L

    Time frame: From baseline up to Days 21, 35, or early temination

  26. Mean Observed Leukocytes Levels

    The mean observed leukocytes levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 4.5-10 10\^9 cells/L

    Time frame: From baseline up to Days 21, 35, or early temination

  27. Mean Observed Lymphocytes Levels

    The mean observed lymphocytes levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 1-4.8 10\^9 cells/L

    Time frame: From baseline up to Days 21, 35, or early temination

  28. Mean Observed Activated Partial Thromboplastin Time

    The mean observed activated partial thromboplastin times in seconds are displayed as measured at the specified timepoints. Baseline is defined as first dose.

    Time frame: From baseline up to Days 21, 35, or early temination

  29. Mean Observed Prothrombin Time

    The mean observed prothrombin times are displayed as measured at the specified timepoints. Baseline is defined as first dose.

    Time frame: From baseline up to Days 21, 35, or early temination

  30. Mean Observed Urinalysis - pH

    The mean observed pH of participants' urine are displayed as measured at the specified timepoints. Baseline is defined as first dose. Urinalysis was completed using dipstick. Urinalysis was not completed if the local dipstick was normal.

    Time frame: From baseline up to Days 21, 35, or early temination

  31. Mean Observed Urinalysis - Prolactin

    The mean observed prolactin levels of participants' urine are displayed as measured at the specified timepoints. Baseline is defined as first dose. Urinalysis was not completed if the local dipstick was normal.

    Time frame: From baseline up to Days 21, 35, or early temination

  32. The Number of Participants With Positive Drug Screen Results

    A National Institute on Drug Abuse-5 urine drug screen (cannabinoids or marijuana, phencyclidine, amphetamines, opiates, and cocaine) was performed at screening and at baseline (Visit 2a \[Day -1\]). If a participant left the study site, they were to have a urine drug screen and test for alcohol (breathalyzer or urine alcohol level) upon returning to the study site.

    Time frame: At screening, at Dat -1, and upon return from departure from study site at any time up to Day 42

  33. The Number of Participants With Elevated Liver Function Test Results

    The liver function test results (ALT, AST, ALP, total bilirubin, GGT) were specifically monitored to watch for any participants who met the FDA drug-induced liver injury (DILI) criteria. A summary of elevated liver function test results by visit is provided. Baseline is defined as measurements taken at screening. Monitoring for DILI criteria includes close observation initiated with ALT or AST \>3 × ULN; discontinuation of treatment should be considered if ALT or AST \>8 × ULN, ALT or AST \>5 × ULN for more than 2 weeks, ALT or AST \>3 × ULN and (total bilirubin \>2 × ULN or international normalized ratio \>1.5), or ALT or AST \>3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia (\>5%).

    Time frame: From screening up to Day 42

07

Results

Posted Dec 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneKarXTPlacebo
Started125131
Recieved treatment125128
Completed7993
Not completed4638
Withdrew: Changes in condition making participant ineligible for further treatment10
Withdrew: Progressive disease04
Withdrew: Adverse event87
Withdrew: Other reasons01
Withdrew: Suicidal or assaultive behavior02
Withdrew: Protocol violation22
Withdrew: Consent withdrawn3522

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5

The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of participants with schizophrenia and is widely used in the study of antipsychotic therapy. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility, and the negative symptoms in schizophrenia are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as the PANSS score at screening.

Time frame:
From baseline up to Week 5
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5
Score on a scaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5-20.6 ± 1.584-12.2 ± 1.552
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5

PANSS positive score is the sum of all PANSS 7 positive symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility. If a patient has a PANSS assessment recorded and no more than 2 items are missing from the PANSS positive scales, then the PANSS Positive Score will be calculated as the average of the non-missing items multiplied by 7. If 3 or more items are missing (\> 30%) at a particular visit, the respective positive score at the visit will not be calculated and will be treated as missing data. Baseline is defined as the PANSS score at screening.

Time frame:
From baseline up to Week 5
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5
Score on a scaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5-7.1 ± 0.499-3.6 ± 0.492
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5

PANSS negative score is the sum of all PANSS 7 negative symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The negative symptoms in schizophrenia are the diminution or loss of normal functions. If a participant has a PANSS assessment recorded, and no more than 2 items are missing from the PANSS negative scales, then the PANSS Negative Score will be calculated as the average of the non-missing items multiplied by 7. If 3 or more items are missing (\> 30%) at a particular visit, the respective negative score at the visit will not be calculated and will be treated as missing data. Baseline is defined as the PANSS score at screening.

Time frame:
From baseline up to Week 5
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5
Score on a scaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5-2.7 ± 0.412-1.8 ± 0.405
SecondaryPositive and Negative Syndrome Scale (PANSS) Negative Marder Factor Score Change From Baseline at Week 5

PANSS Marder factor score is the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom scale. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Baseline is defined as the PANSS score at screening.

Time frame:
From baseline up to Week 5
Reported as:
Least squares mean · Score on a scale
Positive and Negative Syndrome Scale (PANSS) Negative Marder Factor Score Change From Baseline at Week 5
Score on a scaleKarXTPlacebo
Positive and Negative Syndrome Scale (PANSS) Negative Marder Factor Score Change From Baseline at Week 5-3.5 ± 0.484-2.7 ± 0.475
SecondaryClinical Global Impression-Severity (CGI-S) Score Change From Baseline at Week 5

Clinical Global Impression-Severity (CGI-S) Score is a measurement to evaluate severity and treatment response in schizophrenia. Completed independently by a clinician, the CGI-S assesses extremely ill patients, by asking 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness. The CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients. This scale reflects the total score. Baseline is defined as CGI-S score at screening. The change from baseline in total score is reported.

Time frame:
From baseline up to Week 5
Reported as:
Least squares mean · Score on a scale
Clinical Global Impression-Severity (CGI-S) Score Change From Baseline at Week 5
Score on a scaleKarXTPlacebo
Clinical Global Impression-Severity (CGI-S) Score Change From Baseline at Week 5-1.1 ± 0.091-0.6 ± 0.088
SecondaryNumber of Participants Who Achieve >=30% Reduction in Positive and Negative Symptoms Scale (PANSS) Total Score From Baseline to Week 5

Positive and Negative Syndrome Scale (PANSS) is a scale used for measuring symptom severity of subjects with schizophrenia and is widely used in the study of antipsychotic therapy. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Subjects are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility, and the negative symptoms in schizophrenia are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as screening. Note: Floor adjusted data were used for this analysis. Floor adjusted total score = total score - 30.

Time frame:
From baseline up to Week 5
Reported as:
Count of participants · Participants
Number of Participants Who Achieve >=30% Reduction in Positive and Negative Symptoms Scale (PANSS) Total Score From Baseline to Week 5
ParticipantsKarXTPlacebo
Number of Participants Who Achieve >=30% Reduction in Positive and Negative Symptoms Scale (PANSS) Total Score From Baseline to Week 54023
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose up to Day 42
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsKarXTPlacebo
Number of Participants Experiencing Adverse Events (AEs)8864
SecondaryNumber of Participants Experiencing Cholinergic Symptom Adverse Event

The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.

Time frame:
From first dose up to Day 42
Reported as:
Count of participants · Participants
Number of Participants Experiencing Cholinergic Symptom Adverse Event
ParticipantsKarXTPlacebo
At Least One Procholinergic Symptom Adverse Event383
At Least One Anticholinergic Symptom Adverse Event338
SecondaryChange From Baseline in Simpson-Angus Scale Total Score (SAS)

The Simpson-Angus Scale (SAS) is an established instrument to measure drug-related extrapyramidal syndromes. It is a 10-item testing instrument used to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. The range of scores is from 0 to 40 with increased scores indicating increased severity. Baseline is defined as the Simpson-Angus Scale score recorded on Day -1.

Time frame:
From baseline up to week 5
Reported as:
Mean · Score on a Scale
Change From Baseline in Simpson-Angus Scale Total Score (SAS)
Score on a ScaleKarXTPlacebo
Change From Baseline in Simpson-Angus Scale Total Score (SAS)-0.1 ± 0.56-0.1 ± 0.36
SecondaryChange From Baseline in Barnes Akathisia Rating Scale (BARS) Total Score

The BARS for akathisia is a rating scale used to assess the severity of drug-induced akathisia, or restlessness, involuntary movements and inability to sit still. The range of scores is 0 to 14, with higher scores indicating greater severity. Baseline is defined as the BARS score recorded on Day -1.

Time frame:
From baseline up to week 5
Reported as:
Mean · Score on a Scale
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Total Score
Score on a ScaleKarXTPlacebo
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Total Score-0.1 ± 0.75-0.1 ± 0.88
SecondaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score

The AIMS is a rating scale that is used to measure involuntary movements known as tardive dyskinesia, which can sometimes develop as a side effect of long-term treatment with antipsychotic medications. This measurement was a 12-item scale to assess orofacial, extremity, and truncal movements as well as the overall severity, incapacitation, and the participant's level of awareness of the movements. Items are scored from 0 (none) to 4 (severe). A higher score indicates more severe dyskinesia. Baseline is defined as the AIMS score recorded on Day -1. The total score is the sum of sub scores for items 1-7. The first 7 items are used to measure the severity of abnormal movements in the orofacial region (4 items: facial muscles, lips, jaw, tongue), upper extremities (1 item), lower extremities (1 item), and trunk (1 item). Change from baseline for the total scores are reported.

Time frame:
From baseline up to week 5
Reported as:
Mean · Units on a Scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
Units on a ScaleKarXTPlacebo
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score0.0 ± 0.450.0 ± 0.15
SecondaryNumber of Participants Who Experienced Weight Change

The number of participants who lost weight, maintained their weight, or gained weight between baseline and week 5. Baseline is defined as measurements taken at screening.

Time frame:
From baseline up to week 5
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Weight Change
ParticipantsKarXTPlacebo
Lost Weight10
Maintained Weight17280
Gained Weight512
SecondaryChange From Baseline in Body Mass Index (BMI)

The change in Body Mass Index (BMI) from baseline up to week 5. BMI is a person's weight in kilograms divided by the square of height in meters. Baseline is defined as measurements taken at screening.

Time frame:
From baseline up to week 5
Reported as:
Mean · kg/m^2
Change From Baseline in Body Mass Index (BMI)
kg/m^2KarXTPlacebo
Change From Baseline in Body Mass Index (BMI)0.457 ± 1.13400.666 ± 0.570
SecondaryChange From Baseline in Waist Circumference

The change in waist circumference in centimeters from baseline up to week 5. Baseline is defined as measurements taken at screening.

Time frame:
From baseline up to week 5
Reported as:
Mean · Centimeters
Change From Baseline in Waist Circumference
CentimetersKarXTPlacebo
Change From Baseline in Waist Circumference1.666 ± 4.89151.697 ± 4.8577
SecondaryChange From Baseline in Orthostatic Vital Signs - Blood Pressure

The change from baseline in orthostatic diastolic and systolic blood pressure measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.

Time frame:
From baseline up to week 5
Reported as:
Mean · mmHg
Change From Baseline in Orthostatic Vital Signs - Blood Pressure
mmHgKarXTPlacebo
Supine Systolic Blood Pressure1.9 ± 13.070.4 ± 13.00
Supine Diastolic Blood Pressure2.2 ± 10.330.4 ± 9.30
Standing Systolic Blood Pressure2.3 ± 14.070.1 ± 12.54
Standing Diastolic Blood Pressure2.7 ± 9.930.1 ± 8.62
SecondaryChange From Baseline in Orthostatic Vital Signs - Heart Rate

The change from baseline in orthostatic heart rate measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.

Time frame:
From baseline up to week 5
Reported as:
Mean · beats/min
Change From Baseline in Orthostatic Vital Signs - Heart Rate
beats/minKarXTPlacebo
Supine Heart Rate11.9 ± 15.726.1 ± 14.02
Standing Heart Rate9.86 ± 16.585.8 ± 13.85
SecondaryChange From Baseline in Electrocardiogram (ECG) Mean Heart Rate

The change from baseline up to Day 35 or early termination in ECG mean heart rate. Baseline is defined as measurements taken at screening.

Time frame:
From baseline up to Day 35 or early termination
Reported as:
Mean · beats/min
Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate
beats/minKarXTPlacebo
Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate11.5 ± 14.946.1 ± 14.62
SecondaryNumber of Participants Experiencing Clinically Significant Abnormal Physical Examination Results

The number of participants experiencing clinically significant abnormal physical examination results. Baseline is defined as measurements taken at screening.

Time frame:
From baseline up to week 5
Reported as:
Count of participants · Participants
Number of Participants Experiencing Clinically Significant Abnormal Physical Examination Results
ParticipantsKarXTPlacebo
General Appearance - Baseline01
General Appearance - Day 3500
Head, Eyes, Ears, Nose, Throat - Baseline00
Head, Eyes, Ears, Nose, Throat - Day 3500
Thorax - Baseline00
Thorax - Day 3500
Abdomen - Baseline10
Abdomen - Day 3500
Cardiac - Baseline10
Cardiac - Day 3500
Musculoskeletal - Baseline00
Musculoskeletal - Day 3500
Circulatory System - Baseline00
Circulatory System - Day 3500
Lymphadenopathy - Baseline00
Lymphadenopathy - Day 3500
Limited Neurological Examination - Baseline10
Limited Neurological Examination - Day 3500
SecondaryNumber of Participants Experiencing Each Suicidal Ideation Scale Category as Per Columbia Suicide Severity Rating Scale (C-SSRS)

C-SSRS assesses suicidal behavior and ideation on a scale with 4 general categories: suicidal ideation, intensity of ideation, suicidal behavior, and actual attempts. C-SSRS comprehensively identifies suicidal events while limiting the over identification of suicidal behavior. The C-SSRS was administered by a trained rater at the site. This study used 2 versions of the C-SSRS. At the Screening Visit, the "Lifetime" version was completed; for all subsequent visits, the "Since Last Visit" version of the C-SSRS was administered. Risk for suicidal behavior during the study was determined by the investigator's clinical assessment and C-SSRS as confirmed by the following: * Answering "Yes" on items 4 or 5 (C-SSRS - ideation) with the most recent episode occurring within the 2 months before screening, or * Answering "Yes" to any of the 5 items (C-SSRS behavior) with an episode occurring within the 12 months before screening. Non-suicidal, self-injurious behavior is not exclusionary.

Time frame:
From screening up to Day 42
Reported as:
Count of participants · Participants
Number of Participants Experiencing Each Suicidal Ideation Scale Category as Per Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsKarXTPlacebo
Suicidal Ideation: Participant Wished to be Dead13
Suicidal Ideation: Non-Specific Active Suicidal Thoughts11
Suicidal Ideation: Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act01
Most Severe Ideation Level 1. Least Severe02
Most Severe Ideation Level 210
Most Severe Ideation Level 301
Intensity of Ideation (Frequency) - Less than once a week01
Intensity of Ideation (Frequency) - Once a week01
Intensity of Ideation (Frequency) - 2-5 times a week11
Intensity of Ideation (Duration) - Fleeting, a few seconds or minutes13
Controllability - Easily able to control thoughts03
Controllability - Can control thoughts with little difficulty10
Deterrents - Does not apply01
Deterrents - Deterrents definitely stopped participant from attempting suicide12
Reasons for Ideation - Does not apply02
Reasons for Ideation - Mostly to end or stop the pain01
Reasons for Ideation - Completely to end or stop the pain10
SecondaryArea Under the Plasma Concentration-Time Curve (AUC)

AUC is the total area under the plasma drug concentration-time curve from time zero to 12 hours after drug administration. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.

Time frame:
At days 8 and 28
Reported as:
Mean · h*pg/mL
Area Under the Plasma Concentration-Time Curve (AUC)
h*pg/mLKarXTPlacebo
Trospium27800 ± 26000—
Xanomeline50200 ± 37900—
SecondaryMaximum Concentration (Cmax)

Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.

Time frame:
At days 8 and 28
Reported as:
Mean · pg/mL
Maximum Concentration (Cmax)
pg/mLKarXTPlacebo
Trospium6070 ± 7780—
Xanomeline9660 ± 10500—
SecondaryTime to Maximum Concentration (Tmax)

Tmax is defined as the time it takes for a drug to reach the maximum concentration (Cmax) after administration of a drug. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.

Time frame:
At days 8 and 28
Reported as:
Median · Hours
Time to Maximum Concentration (Tmax)
HoursKarXTPlacebo
Trospium1.00 (0.00 to 3.95)—
Xanomeline2.00 (0.00 to 12.00)—
SecondaryMean Observed Hemoglobin Levels

The mean observed Hemoglobin levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 138 - 172 g/L Female: 121 - 151 g/L

Time frame:
From baseline up to Days 21, 35, or early temination
Reported as:
Mean · g/L
Mean Observed Hemoglobin Levels
g/LKarXTPlacebo
Baseline142.30 ± 18.098142.71 ± 15.166
Week 3 (Visit 7 [Day 21])144.54 ± 19.096146.27 ± 14.335
Week 5 (Visit 10 [Day 35])/Early-Termination142.94 ± 19.175144.40 ± 15.416
SecondaryMean Observed Hematocrit Levels

The mean observed Hematocrit levels are displayed in percentages as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 40.7 - 50.3% Female: 36.1 - 44.3%

Time frame:
From baseline up to Days 21, 35, or early temination
Reported as:
Mean · Percentage
Mean Observed Hematocrit Levels
PercentageKarXTPlacebo
Baseline44.52 ± 5.23244.51 ± 4.553
Week 3 (Visit 7 [Day 21])45.12 ± 5.41645.25 ± 4.306
Week 5 (Visit 10 [Day 35])/Early-Termination44.51 ± 5.49144.71 ± 4.595
SecondaryMean Observed Erythrocyte Levels

The mean observed erythrocyte levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 4.7 - 6.1 10\^12 cells/L Female: 4.2 - 5.4 10\^12 cells/L

Time frame:
From baseline up to Days 21, 35, or early temination
Reported as:
Mean · 10^12 cells/L
Mean Observed Erythrocyte Levels
10^12 cells/LKarXTPlacebo
Baseline5.025 ± 0.50724.894 ± 0.4498
Week 3 (Visit 7 [Day 21])5.130 ± 0.49865.165 ± 1.2161
Week 5 (Visit 10 [Day 35])/Early-Termination5.058 ± 0.53395.003 ± 0.5139
SecondaryMean Observed Platelets Levels

The mean observed platelet levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 150-450 10\^9 cells/L

Time frame:
From baseline up to Days 21, 35, or early temination
Reported as:
Mean · 10^9 cells/L
Mean Observed Platelets Levels
10^9 cells/LKarXTPlacebo
Baseline334.04 ± 96.465328.65 ± 92.288
Week 3 (Visit 7 [Day 21])334.47 ± 80.273320.21 ± 73.757
Week 5 (Visit 10 [Day 35])/Early-Termination336.59 ± 88.455327.91 ± 75.834
SecondaryMean Observed Leukocytes Levels

The mean observed leukocytes levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 4.5-10 10\^9 cells/L

Time frame:
From baseline up to Days 21, 35, or early temination
Reported as:
Mean · 10^9 cells/L
Mean Observed Leukocytes Levels
10^9 cells/LKarXTPlacebo
Baseline5.971 ± 1.94656.384 ± 2.1421
Week 3 (Visit 7 [Day 21])6.046 ± 1.80906.252 ± 1.6685
Week 5 (Visit 10 [Day 35])/Early-Termination6.199 ± 2.18146.184 ± 1.7208
SecondaryMean Observed Lymphocytes Levels

The mean observed lymphocytes levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 1-4.8 10\^9 cells/L

Time frame:
From baseline up to Days 21, 35, or early temination
Reported as:
Mean · 10^9 cells/L
Mean Observed Lymphocytes Levels
10^9 cells/LKarXTPlacebo
Baseline2.749 ± 0.94083.094 ± 3.9283
Week 3 (Visit 7 [Day 21])2.834 ± 0.98902.976 ± 0.9431
Week 5 (Visit 10 [Day 35])/Early-Termination3.000 ± 1.27482.792 ± 0.8456
SecondaryMean Observed Activated Partial Thromboplastin Time

The mean observed activated partial thromboplastin times in seconds are displayed as measured at the specified timepoints. Baseline is defined as first dose.

Time frame:
From baseline up to Days 21, 35, or early temination
Reported as:
Mean · Seconds
Mean Observed Activated Partial Thromboplastin Time
SecondsKarXTPlacebo
Baseline30.75 ± 4.41231.75 ± 5.897
Week 3 (Visit 7 [Day 21])32.43 ± 4.79833.55 ± 7.858
Week 5 (Visit 10 [Day 35])/Early-Termination31.48 ± 3.63633.04 ± 6.775
SecondaryMean Observed Prothrombin Time

The mean observed prothrombin times are displayed as measured at the specified timepoints. Baseline is defined as first dose.

Time frame:
From baseline up to Days 21, 35, or early temination
Reported as:
Mean · Seconds
Mean Observed Prothrombin Time
SecondsKarXTPlacebo
Baseline1.00 ± 0.0911.01 ± 0.086
Week 3 (Visit 7 [Day 21])1.02 ± 0.0961.00 ± 0.086
Week 5 (Visit 10 [Day 35])/Early-Termination1.01 ± 0.0781.00 ± 0.083
SecondaryMean Observed Urinalysis - pH

The mean observed pH of participants' urine are displayed as measured at the specified timepoints. Baseline is defined as first dose. Urinalysis was completed using dipstick. Urinalysis was not completed if the local dipstick was normal.

Time frame:
From baseline up to Days 21, 35, or early temination
Reported as:
Mean · pH
Mean Observed Urinalysis - pH
pHKarXTPlacebo
Baseline5.52 ± 0.6765.59 ± 0.800
Week 3 (Visit 7 [Day 21])5.33 ± 0.4765.48 ± 0.748
Week 5 (Visit 10 [Day 35]/Early Termination)5.48 ± 0.6875.45 ± 0.621
SecondaryMean Observed Urinalysis - Prolactin

The mean observed prolactin levels of participants' urine are displayed as measured at the specified timepoints. Baseline is defined as first dose. Urinalysis was not completed if the local dipstick was normal.

Time frame:
From baseline up to Days 21, 35, or early temination
Reported as:
Mean · ug/L
Mean Observed Urinalysis - Prolactin
ug/LKarXTPlacebo
Baseline18.08 ± 21.76717.38 ± 21.920
Week 3 (Visit 7 [Day 21])17.49 ± 19.42214.50 ± 12.064
Week 5 (Visit 10 [Day 35]/Early Termination)19.46 ± 24.66815.56 ± 13.463
SecondaryThe Number of Participants With Positive Drug Screen Results

A National Institute on Drug Abuse-5 urine drug screen (cannabinoids or marijuana, phencyclidine, amphetamines, opiates, and cocaine) was performed at screening and at baseline (Visit 2a \[Day -1\]). If a participant left the study site, they were to have a urine drug screen and test for alcohol (breathalyzer or urine alcohol level) upon returning to the study site.

Time frame:
At screening, at Dat -1, and upon return from departure from study site at any time up to Day 42
Reported as:
Count of participants · Participants
The Number of Participants With Positive Drug Screen Results
ParticipantsKarXTPlacebo
The Number of Participants With Positive Drug Screen Results31
SecondaryThe Number of Participants With Elevated Liver Function Test Results

The liver function test results (ALT, AST, ALP, total bilirubin, GGT) were specifically monitored to watch for any participants who met the FDA drug-induced liver injury (DILI) criteria. A summary of elevated liver function test results by visit is provided. Baseline is defined as measurements taken at screening. Monitoring for DILI criteria includes close observation initiated with ALT or AST \>3 × ULN; discontinuation of treatment should be considered if ALT or AST \>8 × ULN, ALT or AST \>5 × ULN for more than 2 weeks, ALT or AST \>3 × ULN and (total bilirubin \>2 × ULN or international normalized ratio \>1.5), or ALT or AST \>3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia (\>5%).

Time frame:
From screening up to Day 42
Reported as:
Count of participants · Participants
The Number of Participants With Elevated Liver Function Test Results
ParticipantsKarXTPlacebo
Baseline - Bilirubin (umol/L) > 1. 5 x ULN10
Baseline - Gamma Glutamyl Transferase (U/L) > 2 x ULN44
Baseline - Alanine Aminotransferase (U/L) > 3 x ULN00
Baseline - Aspartate Aminotransferase (U/L) > 3 x ULN00
Baseline - Alkaline Phosphatase (U/L) > 105 x ULN00
Baseline - Hy's Law Cases00
Visit 4 Day 7 - Gamma Glutamyl Transferase (U/L) > 2 x ULN01
Visit 7 Day 21 - Alanine Aminotransferase (U/L) > 3 x ULN10
Visit 7 Day 21 - Alanine Aminotransferase (U/L) > 5 x ULN20
Visit 7 Day 21 - Aspartate Aminotransferase (U/L) > 3 x ULN10
Visit 7 Day 21 - Alkaline Phosphatase (U/L) > 2 x ULN10
Visit 7 Day 21 - Gamma Glutamyl Transferase (U/L) > 2 x ULN61
Visit 10 Day 35 - Alanine Aminotransferase (U/L) > 3 x ULN01
Visit 10 Day 35 - Alanine Aminotransferase (U/L) > 5 x ULN10
Visit 10 Day 35 - Alkaline Phosphatase (U/L) > 1. 5 x ULN10
Visit 10 Day 35 - Gamma Glutamyl Transferase (U/L) > 2 x ULN41
Visit 10 or Early Termination Alanine Aminotransferase (U/L) >3x ULN01
Visit 10 or Early Termination - Alanine Aminotransferase (U/L) >5x ULN10
Visit 10 or Early Termination - Alkaline Phosphatase (U/L) > 1. 5 x ULN11
Visit 10 or Early Termination - Bilirubin (umol/L) > 2 x ULN10
Visit 10 or Early Termination - Gamma Glutamyl Transferase (U/L) > 2 x ULN71
Visit 11 Day 42 - Bilirubin (umol/L) > 1. 5 x ULN10
Visit 11 Day 42 - Gamma Glutamyl Transferase (U/L) > 2 x ULN30

Adverse events

Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 20 months). SAEs and Other AEs were assessed from first dose up to Day 42.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
KarXT0/125 (0%)1/125 (0.8%)69/125 (55.2%)
Placebo0/131 (0%)0/128 (0%)36/128 (28.1%)
Most frequent serious events
Most frequent serious events
EventKarXTPlacebo
Gastrooesophageal reflux diseaseGastrointestinal disorders1/1250/128
Most frequent other events
Most frequent other events
EventKarXTPlacebo
NauseaGastrointestinal disorders24/1252/128
DyspepsiaGastrointestinal disorders20/1252/128
VomitingGastrointestinal disorders20/1251/128
ConstipationGastrointestinal disorders16/1255/128
HeadacheNervous system disorders14/12515/128
InsomniaPsychiatric disorders7/12510/128
HypertensionVascular disorders8/1252/128
AnxietyPsychiatric disorders2/1258/128
DiarrhoeaGastrointestinal disorders7/1251/128

Baseline characteristics

Age, Continuous
Age, Continuous(Years)KarXTPlaceboTotal
Mean43.6 ± 11.4442.6 ± 12.1943.1 ± 11.82
Sex: Female, Male
Sex: Female, Male(Participants)KarXTPlaceboTotal
Female382765
Male87104191
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)KarXTPlaceboTotal
Hispanic or Latino181432
Not Hispanic or Latino107117224
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)KarXTPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American7977156
White455398
More than one race000
Unknown or Not Reported011
08

Study locations

32 sites
  • Pillar Clinical Research
    Bentonville, Arkansas 72712, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • Clinical Innovations, Inc
    Bellflower, California 90706, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Collaborative Neuroscience Research, LLC.
    Garden Grove, California 92845, United States
  • CNS Network
    Long Beach, California 90806, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Behavioral Clinical Research, Inc.
    Hollywood, Florida 33021, United States
  • Larkin Behavioral Health Services
    Hollywood, Florida 33021, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • AMITA Health Center for Psychiatric Research
    Chicago, Illinois 60622, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • AMITA Health Center for Psychiatric Research
    Hoffman Estates, Illinois 60169, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • InSite Clinical Research, LLC
    DeSoto, Texas 75115, United States
  • Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov
    Dnipro, 49005, Ukraine
  • Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine
    Kharkiv, 61068, Ukraine
  • Regional Clinical Psychiatric Hospital No. 3, Adult Psychiatric Department No. 3
    Kharkiv, 61068, Ukraine
  • Regional Clinical Psychiatric Hospital No. 3, Psychiatric Department for First Episode Psychosis
    Kharkiv, 61068, Ukraine
  • Kherson Regional Institution of Mental Care
    Kherson, 73488, Ukraine
  • Kyiv City Psychoneurological Hospital #2
    Kyiv, 02192, Ukraine
  • Kyiv Regional Medical Incorporation "Psychiatry", Center for Novel Treatment and Rehabilitation of Psychotic Disorders
    Kyiv, 04080, Ukraine
  • Lviv Regional Clinical Psychiatric Hospital, Department #20
    Lviv, 79021, Ukraine
  • Lviv Regional Clinical Psychiatric Hospital, Department #25
    Lviv, 79021, Ukraine
  • Regional Institution of Mental Psychiatric Care of the Poltava Regional Council
    Poltava, 36013, Ukraine
  • Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council
    Smila, 20708, Ukraine
  • M.I. Pyrogov Vinnytsya National Medical University
    Vinnytsya, 21037, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Nov 2022, 19 months.

Results were first posted in Dec 2024, 2 years after primary completion. A results delay was requested in Oct 2023.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 19 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2021
First posted
Feb 4, 2021
StartActual
Apr 6, 2021
Primary completionActual
Nov 29, 2022
CompletionActual
Dec 7, 2022
Results delay requested
Oct 27, 2023
Results first posted
Dec 9, 2024
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04738123
Responsible party
Sponsor
First posted
Feb 4, 2021
Start date
Apr 6, 2021
Primary completion
Nov 29, 2022
Completion
Dec 7, 2022
Results posted
Dec 9, 2024
Last update
Dec 9, 2024

Study contacts

Inder Kaul, MD
study director · Karuna Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion